These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 27645365)

  • 1. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
    Aslanyan A; Anwar-Hashim Z; Siripurapu R; Mihalova T
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
    Walker S; Brew B
    J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
    Sharim J; Tashjian R; Golzy N; Pouratian N
    J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
    J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
    [No Abstract]   [Full Text] [Related]  

  • 8. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
    Christopher KL; Elner VM; Demirci H
    Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
    J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 11. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
    Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
    Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
    Navardi S; Sahraian MA
    Mult Scler Relat Disord; 2018 Apr; 21():69-70. PubMed ID: 29474980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
    De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
    Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection.
    Saccà F; Pane C; De Rosa A; Matarazzo M; Brescia Morra V
    Neurol Sci; 2017 Mar; 38(3):501-502. PubMed ID: 27699497
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
    Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
    Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
    Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
    Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
    Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Samaraweera AP; Cohen SN; Akay EM; Evangelou N
    Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes zoster laryngitis in a patient treated with fingolimod.
    Hagiya H; Yoshida H; Shimizu M; Motooka D; Nakamura S; Iida T; Yamamoto N; Akeda Y; Tomono K
    J Infect Chemother; 2016 Dec; 22(12):830-832. PubMed ID: 27553068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.